Unravelling physical and radiobiological effects of proton boron fusion reaction with anionic metallacarboranes ([o-COSAN]-) in breast cancer cells

EJNMMI Research, Journal Year: 2025, Volume and Issue: 15(1)

Published: Feb. 21, 2025

Abstract Background Protons, which are considered low-LET (Linear Energy Transfer) radiation, have an average RBE (relative biological effectiveness) of 1.1, with a range from 0.7 to 1.6. Thus, increasing effectiveness is high interest in radiation oncology, and one way enhance this by using radiosensitizers. The present work investigates the proton boron fusion reaction (PBFR) at cellular level, sodium salt metallacarborane [3,3’-Co(C2B9H11)2] − (Na[o-COSAN]) as source, aiming explore potential type clusters radiosensitizer for therapy. Therefore, main goal was test hypothesis that loading cells will favour PBFR energies close Bragg peak. This would radiation-induced effects through production alpha-particles. Results MDA-MB-231 breast cancer were used. Nuclear microscopy assessed [o-COSAN] uptake distribution single cells, while biodistribution studied tumor-bearing Balb/cSlc-nu/nu mice (MDA-MB-231 xenograft), accumulation target organs tumor measured ICP-OES. irradiated beam tuned reach resonance energy 675 keV cell layer. DNA damage g-H2AX assay survival clonogenic assay. Beam parameters dose calibration curves radiochromic films validated Monte Carlo dosimetry simulations. As expected, we observed higher presence potentiated damage. These results translate into lower viability, indicating imposed colonies smaller than their non-irradiated counterparts. suggests these damages either took longer time be repaired or made undergo less efficient mechanisms. Conclusions radiosensitizing effect strategic 11 B placement irradiation intensifies damage, making nucleus particularly susceptible thus destructive capability alpha-particles, generated nuclear reaction, may lead increased mortality.

Language: Английский

Liposomal nanoformulations of novel copper-based complexes exhibiting antimelanoma activity – In vitro and in vivo validation

International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125643 - 125643

Published: April 1, 2025

Language: Английский